{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:07:05Z","timestamp":1792465625490,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30AR072583"],"award-info":[{"award-number":["P30AR072583"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR002369"],"award-info":[{"award-number":["UL1TR002369"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ard.2026.01.002","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:39:08Z","timestamp":1770727148000},"page":"787-796","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1108-019X","authenticated-orcid":false,"given":"Jeremy A","family":"Hawkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A R","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E","family":"Huffstutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Loveless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Gharib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmugapriya","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashree","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ridley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilhem","family":"Messaoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Kyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Bong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-6947","authenticated-orcid":false,"given":"Kevin L","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ard.2026.01.002_bib0001","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3899\/jrheum.220986","article-title":"Incidence of herpes zoster in patients with rheumatoid arthritis in the United States: a retrospective cohort study","volume":"50","author":"Singer","year":"2023","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2026.01.002_bib0002","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","article-title":"Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2026.01.002_bib0003","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"issue":"22","key":"10.1016\/j.ard.2026.01.002_bib0004","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ard.2026.01.002_bib0005","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/cid\/ciab629","article-title":"The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70","volume":"74","author":"Boutry","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ard.2026.01.002_bib0006","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ard.2026.01.002_bib0007","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"10.1016\/j.ard.2026.01.002_bib0008","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/S2665-9913(24)00084-5","article-title":"Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Park","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2026.01.002_bib0009","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ard.2026.01.002_bib0010","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ard.2025.01.045","article-title":"Effectiveness and safety of the recombinant zoster vaccine in individuals \u226550 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study","volume":"84","author":"Rayens","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.01.002_bib0011","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13075-025-03565-0","article-title":"Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster","volume":"27","author":"Curtis","year":"2025","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.ard.2026.01.002_bib0012","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","article-title":"Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"80","author":"Friedman","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"42","key":"10.1016\/j.ard.2026.01.002_bib0013","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1016\/j.vaccine.2013.07.086","article-title":"Effect of abatacept on immunogenicity of vaccines in individuals with type 1 diabetes","volume":"31","author":"Weinberg","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.ard.2026.01.002_bib0014","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1186\/ar4358","article-title":"Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis","volume":"15","author":"Crnkic Kapetanovic","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"15","key":"10.1016\/j.ard.2026.01.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.168663","article-title":"Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune-modifying therapies","volume":"8","author":"Klebanoff","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.ard.2026.01.002_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.740249","article-title":"ImmunosuppressiveTherapies differently modulate humoral- and T-cell-Specific responses to COVID-19 mRNA vaccine in rheumatoid arthritis patients","volume":"12","author":"Picchianti-Diamanti","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ard.2026.01.002_bib0017","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/ar2174","article-title":"Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects","volume":"9","author":"Tay","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.ard.2026.01.002_bib0018","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3899\/jrheum.161145","article-title":"Content and construct validity, reliability, and responsiveness of the rheumatoid arthritis flare questionnaire: OMERACT 2016 workshop report","volume":"44","author":"Bartlett","year":"2017","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.01.002_bib0019","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ard.2026.01.002_bib0020","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.ard.2026.01.002_bib0021","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00240-21","article-title":"Comparative antibody responses to the live-attenuated and recombinant herpes zoster vaccines","volume":"95","author":"Schmid","year":"2021","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.ard.2026.01.002_bib0022","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1172\/JCI121484","article-title":"Th1 memory differentiates recombinant from live herpes zoster vaccines","volume":"128","author":"Levin","year":"2018","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.ard.2026.01.002_bib0023","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/infdis\/jiab580","article-title":"Cell-mediated immune responses after administration of the live or the recombinant zoster vaccine: 5-year persistence","volume":"225","author":"Johnson","year":"2022","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.ard.2026.01.002_bib0024","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1093\/infdis\/jiy383","article-title":"Comparative immune responses to licensed herpes zoster vaccines","volume":"218","author":"Weinberg","year":"2018","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.ard.2026.01.002_bib0025","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1128\/CVI.00342-08","article-title":"Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization","volume":"16","author":"Weinberg","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"10","key":"10.1016\/j.ard.2026.01.002_bib0026","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","article-title":"Validation of rheumatoid arthritis improvement criteria that include simplified joint counts","volume":"41","author":"van Gestel","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.ard.2026.01.002_bib0027","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1136\/annrheumdis-2012-202281","article-title":"Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study","volume":"72","author":"van der Maas","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ard.2026.01.002_bib0028","doi-asserted-by":"crossref","first-page":"ofac485","DOI":"10.1093\/ofid\/ofac485","article-title":"Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination","volume":"9","author":"Strezova","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.ard.2026.01.002_bib0029","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.ard.2026.01.002_bib0030","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1182\/bloodadvances.2020002269","article-title":"Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study","volume":"4","author":"Camargo","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.ard.2026.01.002_bib0031","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in hiv-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2014","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.ard.2026.01.002_bib0032","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/rheumatology\/kead552","article-title":"Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors","volume":"63","author":"K\u00e4llmark","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2026.01.002_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003902","article-title":"Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs","volume":"10","author":"Kojima","year":"2024","journal-title":"RMD Open"},{"issue":"8","key":"10.1016\/j.ard.2026.01.002_bib0034","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.3390\/ijms24086967","article-title":"Immunogenicity and safety of adjuvanted recombinant zoster vaccine in rheumatoid arthritis patients on anti-cellular biologic agents or JAK inhibitors: a prospective observational study","volume":"24","author":"Venerito","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ard.2026.01.002_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005521","article-title":"Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy","volume":"11","author":"Winthrop","year":"2025","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.ard.2026.01.002_bib0036","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/BOR.0000000000000491","article-title":"How does abatacept really work in rheumatoid arthritis?","volume":"30","author":"Bonelli","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2026.01.002_bib0037","first-page":"317","article-title":"Abatacept treatment of patients with primary Sj\u00f6gren's syndrome results in a decrease of germinal centres in salivary gland tissue","volume":"35","author":"Haacke","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2026.01.002_bib0038","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1093\/rheumatology\/keab454","article-title":"Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis","volume":"61","author":"Aldridge","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ard.2026.01.002_bib0039","first-page":"204","article-title":"Reduction of peripheral blood T cells producing IFN-\u03b3 and IL-17 after therapy with abatacept for rheumatoid arthritis","volume":"32","author":"Scarsi","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2026.01.002_bib0040","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.4049\/jimmunol.165.3.1352","article-title":"CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression","volume":"165","author":"Carreno","year":"2000","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.ard.2026.01.002_bib0041","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2026.01.002_bib0042","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2018-213222","article-title":"Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:04:27Z","timestamp":1792267467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726000014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0003496726000014"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.01.002","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}